Core Alternative Capital’s Thermo Fisher Scientific TMO Stock Holding History

Core Alternative Capital’s Portfolio TMO Stock Details TMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.48M	Sell	3,002 -142	-5%	-$77.1K	0.44%	58
2025 Q4	$1.82M	Buy	3,144 +267	+9%	+$151K	0.5%	55
2025 Q3	$1.4M	Sell	2,877 -255	-8%	-$119K	0.41%	56
2025 Q2	$1.27M	Sell	3,132 -739	-19%	-$309K	0.35%	61
2025 Q1	$1.93M	Sell	3,871 -40	-1%	-$21.7K	0.46%	62
2024 Q4	$2.03M	Sell	3,911 -393	-9%	-$216K	0.43%	61
2024 Q3	$2.66M	Buy	4,304 +2	+0%	+$1.18K	0.51%	60
2024 Q2	$2.38M	Buy	4,302 +8	+0.2%	+$4.58K	0.48%	60
2024 Q1	$2.5M	Sell	4,294 -72	-2%	-$40.4K	0.45%	60
2023 Q4	$2.32M	Sell	4,366 -187	-4%	-$90.5K	0.4%	61
2023 Q3	$2.3M	Buy	4,553 +387	+9%	+$206K	0.36%	59
2023 Q2	$2.17M	Buy	4,166 +165	+4%	+$89K	0.32%	62
2023 Q1	$2.31M	Sell	4,001 -762	-16%	-$429K	0.31%	60
2022 Q4	$2.62M	Sell	4,763 -1	-0%	-$530	0.33%	52
2022 Q3	$2.42M	Buy	4,764 +887	+23%	+$496K	0.39%	47
2022 Q2	$2.11M	Buy	3,877 +1,363	+54%	+$750K	0.5%	44
2022 Q1	$1.49M	Buy	2,514 +1,848	+277%	+$1.06M	0.4%	44
2021 Q4	$444K	Buy	666 +619	+1,317%	+$386K	0.09%	70
2021 Q3	$27K	Buy	+47	New	+$25.8K	0.01%	85

Other funds holding TMO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Core Alternative Capital's TMO Position: Q1 2026 in Review

Core Alternative Capital reduced its Thermo Fisher Scientific (TMO) stake by 4.5% in Q1 2026, selling an estimated $77.1K and leaving 3,002 shares worth $1.48M. The position accounts for 0.44% of the portfolio, ranked #58.

Core Alternative Capital first reported a position in TMO in Q3 2021 and has held it in 19 quarters since. The position peaked at $2.66M in Q3 2024. 2,587 funds tracked by Wall St. Rank hold TMO as of Q1 2026.

Core Alternative Capital held 3,002 shares of Thermo Fisher Scientific worth $1.48M as of Q1 2026.
Core Alternative Capital sold 142 Thermo Fisher Scientific shares in Q1 2026, an estimated $77.1K.
Thermo Fisher Scientific made up 0.44% of Core Alternative Capital's portfolio in Q1 2026, its #58 holding.
Core Alternative Capital first reported a position in Thermo Fisher Scientific in Q3 2021 and has held it in 19 quarters since.
Core Alternative Capital's Thermo Fisher Scientific position peaked at $2.66M in Q3 2024.
2,587 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.

Based on Core Alternative Capital's 13F filing for Q1 2026, filed 30 Apr 2026.